Enfoque terapéutico del cáncer gástrico. Revisión de la literatura
Palabras clave:
Neoplasias gástricas, diagnóstico, cirugía, quimioterapia, radioterapiaResumen
El cáncer gástrico es un problema de salud en el mundo y en Colombia; la mayoría de los pacientes se diagnostican con una enfermedad local avanzada y de pronóstico cada vez más pobre. La resección quirúrgica es la base del tratamiento, y se debe realizar con la adecuada selección de los pacientes mediante procesos de estadificación clínica, y, en algunos casos, intervencionista. Debido a las altas tasas de recurrencia locorregional y sistémica, la cirugía debe ser complementada con quimioterapia perioperatoria o quimiorradioterapia adyuvantes, según lo amerite el caso; esto mejora la supervivencia libre de enfermedad y la supervivencia global. Los pacientes que por su estado avanzado no puedan ser manejados con cirugía serán derivados a tratamiento paliativo con quimioterapia o quimiorradioterapia. El estudio y el análisis de estos pacientes deben ser multidisciplinarios, por la complejidad de la patología y la diversidad de opciones de tratamiento.
Biografía del autor/a
Marco Torregroza, Instituto Nacional de Cancerología
Grupo de Oncología Clínica, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Universidad del Bosque, Bogotá D.C., Colombia
Cristina Guarnizo, Instituto Nacional de Cancerología
Subdirección de Investigaciones, Vigilancia Epidemiológica, Promoción y Prevención, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Escuela Juan N. Corpas, Bogotá D.C., Colombia
Referencias bibliográficas
International Agency for Research on Cancer (IARC), World Health Organization (WHO). Globocan 2008: Cancer incidence and mortality worldwide in 2008. Lyon: IARC; 2008.
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
https://doi.org/10.3322/CA.2007.0010
Pardo Ramos C, Cendales Duarte R. Incidencia estimada y mortalidad por cáncer en Colombia 2002 -2006. Bogotá: Instituto Nacional de Cancerología; 2010.
Abeloff MD, Armitage JO, Niederhuber JE, et al. Abeloff's clinical oncology. 4a ed. Philadelphia: Churchill Livingstone, Elsevier; 2008.
Graham DY, Schwartz JT, Cain GD, et al. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology. 1982;82:228-31.
https://doi.org/10.1016/0016-5085(82)90009-9
Kurtz RC, Sherlock P. The diagnosis of gastric cancer. Semin Oncol. 1985;12:11-8.
Low VH, Levine MS, Rubesin SE, et al. Diagnosis of gastric carcinoma: sensitivity of double-contrast barium studies. AJR Am J Roentgenol. 1994;162:329-34.
https://doi.org/10.2214/ajr.162.2.8310920
Catalano V, Labianca R, Beretta GD, et al. Gastric cancer. Crit Rev Oncol Hematol. 2009;71:127-64.
https://doi.org/10.1016/j.critrevonc.2009.01.004
Edge SB, Byrd DR, Compton CC, et al, editores. AJCC cancer staging manual. 7a ed. New York: Springer; 2010.
Abdalla EK, Pisters PW. Staging and preoperative evaluation of upper gastrointestinal malignancies. Semin Oncol. 2004;31:513-29.
https://doi.org/10.1053/j.seminoncol.2004.04.014
Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25:2107-16.
https://doi.org/10.1200/JCO.2006.09.5224
Adachi Y, Sakino I, Matsumata T, et al. Preoperative assessment of advanced gastric carcinoma using computed tomography. Am J Gastroenterol. 1997;92:872-5.
Paramo JC, Gómez G. Dynamic CT in the preoperative evaluation of patients with gastric cancer: correlation with surgical findings and pathology. Ann Surg Oncol. 1999;6:379-84.
https://doi.org/10.1007/s10434-999-0379-7
Fukuya T, Honda H, Hayashi T, et al. Lymph-node metastases: efficacy for detection with helical CT in patients with gastric cancer. Radiology. 1995;197:705-11.
https://doi.org/10.1148/radiology.197.3.7480743
Tschmelitsch J, Weiser MR, Karpeh MS. Modern staging in gastric cancer. Surg Oncol. 2000;9:23-30.
https://doi.org/10.1016/S0960-7404(00)00020-7
Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003;30:288-95.
https://doi.org/10.1007/s00259-002-1029-5
Chen J, Cheong JH, Yun MJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer. 2005;103:2383-90.
https://doi.org/10.1002/cncr.21074
Tsendsuren T, Jun SM, Mian XH. Usefulness of endoscopic ultrasonography in preoperative TNM staging of gastric cancer. World J Gastroenterol. 2006;12:43-7.
https://doi.org/10.3748/wjg.v12.i1.43
Stell DA, Carter CR, Stewart I, et al. Prospective comparison of laparoscopy, ultrasonography and computed tomography in the staging of gastric cancer. Br J Surg. 1996;83:1260-2.
https://doi.org/10.1002/bjs.1800830927
Burke EC, Karpeh MS, Conlon KC, et al. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg. 1997;225:262-7.
https://doi.org/10.1097/00000658-199703000-00004
Sarela AI, Leftkowitz R, Brennan MF, et al. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg. 2006;191:134-8.
https://doi.org/10.1016/j.amjsurg.2005.10.015
Bozzetti F, Marubini E, Bonfanti G, et al. Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg. 1997;226:613-20.
https://doi.org/10.1097/00000658-199711000-00006
Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg. 1999;230:170-8.
https://doi.org/10.1097/00000658-199908000-00006
Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Cooperative Group. Br J Cancer. 1999;79:1522-30.
https://doi.org/10.1038/sj.bjc.6690243
Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908-14.
https://doi.org/10.1056/NEJM199903253401202
Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg. 2006;93:559-63.
https://doi.org/10.1002/bjs.5353
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
https://doi.org/10.1056/NEJMoa055531
Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Proc Am Soc Clin Oncol. 2007;25:4510.
Ajani JA, Barthel JS, Bekaii-Saab T, et al. Gastric cancer. J Natl Compr Canc Netw. 2010;8:378-409.
https://doi.org/10.6004/jnccn.2010.0030
Okines A, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v50-4.
https://doi.org/10.1093/annonc/mdq164
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-30.
https://doi.org/10.1056/NEJMoa010187
Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005;63:1279-85.
https://doi.org/10.1016/j.ijrobp.2005.05.005
Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer. 1999;35:1059-64.
https://doi.org/10.1016/S0959-8049(99)00076-3
Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Appararo Digerente). Ann Oncol. 2000;11:837-43.
https://doi.org/10.1023/A:1008377101672
Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori. 2002;88:21-7.
Hu JK, Chen ZX, Zhou ZG, et al. Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials. World J Gastroenterol. 2002;8:1023-8.
https://doi.org/10.3748/wjg.v8.i6.1023
Janunger KG, Hafström L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168:597-608.
https://doi.org/10.1080/11024150201680005
Liu TS, Wang Y, Chen SY, et al. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol. 2008;34:1208-16.
https://doi.org/10.1016/j.ejso.2008.02.002
Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-20.
https://doi.org/10.1056/NEJMoa072252
Wu AW, Xu GW, Wang HY, et al. Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database Syst Rev. 2007;2:CD005047.
https://doi.org/10.1002/14651858.CD005047.pub2
He LF, Yang KH, Tian JH, et al. [Meta-analysis of clinical effectiveness of neoadjuvant chemotherapy for gastric cancer]. Ai Zheng. 2008;27:407-12. Chinese.
Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851-6.
https://doi.org/10.1200/JCO.2008.17.0506
Gallardo-Rincón D, Oñate-Ocaña LF, Calderillo-Ruiz G. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study. Ann Surg Oncol. 2000;7:45-50.
https://doi.org/10.1007/s10434-000-0045-6
Yano M, Shiozaki H, Inoue M, et al. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer. World J Surg. 2002;26:1155-9.
https://doi.org/10.1007/s00268-002-6362-0
Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7.
https://doi.org/10.1200/JCO.2006.06.8429
Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903-9.
https://doi.org/10.1200/JCO.2005.05.0245
Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46.
https://doi.org/10.1056/NEJMoa073149
Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
https://doi.org/10.1016/S1470-2045(08)70035-4
Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol. 2009;27:LBA4509.
https://doi.org/10.1200/jco.2009.27.18s.lba4509
Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999;80:269-72.
https://doi.org/10.1038/sj.bjc.6690350
Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003;21:54-9.
https://doi.org/10.1200/JCO.2003.04.130
Tebbutt NC, Norman A, Cunningham D, et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophagogastric cancer. Ann Oncol. 2002;13:1568-75.
Cómo citar
Descargas
Descargas
Número
Sección
Licencia
Todos los derechos reservados.
